rapamycin
rapamycin is a pharmaceutical drug with 83 clinical trials. Currently 15 active trials ongoing. Historical success rate of 87.5%.
Success Metrics
Based on 49 completed trials
Phase Distribution
Phase Distribution
31
Early Stage
31
Mid Stage
15
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
84.5%
49 of 58 finished
15.5%
9 ended early
15
trials recruiting
83
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)
A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Rapamycin - Effects on Alzheimer's and Cognitive Health
Clinical Trials (83)
Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)
A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Rapamycin - Effects on Alzheimer's and Cognitive Health
RESTOR: PK/PD mTORi Inhibition in Older Adults
Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations
Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis
Combination Gerotherapeutic Interventions for Healthspan Improvement
Daily Topical Rapamycin for Vitiligo
Effect of Rapamycin in Ovarian Aging
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
Rapamycin Treatment for ALS
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 83